EXO Therapeutics

Exo Therapeutics' ExoSight™ platform identifies and targets exosites on enzymes, enabling the development of novel small molecule inhibitors that modulate enzyme activity with precision and potency in previously intractable targets.

The company has completed a Series B financing round and has presented data on novel exosite inhibitors of TBK1 at major scientific conferences including the American College of Rheumatology's Convergence.